N H Hanna

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study
    Nasser Hanna
    Department of Medicine, Indiana University, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202, USA
    Lung Cancer 35:293-7. 2002
  2. ncbi Salvage therapy in patients with advanced non-small cell lung cancer
    Pablo M Bedano
    Department of Medicine, Division of Oncology, Indiana University, Indianapolis, Indiana 46202, USA
    J Thorac Oncol 1:582-7. 2006
  3. ncbi Prognostic factors in stage III non-small-cell lung cancer
    Foluso O Ademuyiwa
    Division of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Clin Lung Cancer 8:478-82. 2007
  4. ncbi Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    Nasser Hanna
    Indiana University, Indianapolis, IN 46202, USA
    J Clin Oncol 24:2038-43. 2006
  5. ncbi Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer
    Nasser Hanna
    Indiana University, Indianapolis, USA
    J Clin Oncol 24:5253-8. 2006
  6. ncbi Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology
    Nasser Hanna
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA
    J Clin Oncol 26:5755-60. 2008
  7. ncbi Advances in the treatment of second-line non-small-cell lung cancer
    N Hanna
    Indiana University, Indianapolis, IN 46202, USA
    Lung Cancer 50:S15-7. 2005
  8. ncbi Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Nasser Hanna
    Indiana University, 535 Barnhill Dr, Room 473, Indianapolis, IN 46202, USA
    J Clin Oncol 22:1589-97. 2004
  9. ncbi Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed
    Nasser H Hanna
    Department of Medicine, Indiana University, Indianapolis 46202, USA
    Clin Lung Cancer 5:S75-9. 2004
  10. ncbi Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study
    N H Hanna
    Department of Medicine, Indiana University Medical Center, Indianapolis, USA
    Ann Oncol 13:95-102. 2002

Detail Information

Publications33

  1. ncbi Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study
    Nasser Hanna
    Department of Medicine, Indiana University, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202, USA
    Lung Cancer 35:293-7. 2002
    ..In addition, treatment-related morbidity and mortality appears to be unacceptably high with the VIP regimen...
  2. ncbi Salvage therapy in patients with advanced non-small cell lung cancer
    Pablo M Bedano
    Department of Medicine, Division of Oncology, Indiana University, Indianapolis, Indiana 46202, USA
    J Thorac Oncol 1:582-7. 2006
    ..Lastly, we propose strategies to advance the treatment of patients with non-small cell lung cancer...
  3. ncbi Prognostic factors in stage III non-small-cell lung cancer
    Foluso O Ademuyiwa
    Division of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Clin Lung Cancer 8:478-82. 2007
    ..The aim of this study is to present an analysis investigating the association of patient characteristics with overall survival (OS) in individuals with stage III non-small-cell lung cancer (NSCLC)...
  4. ncbi Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    Nasser Hanna
    Indiana University, Indianapolis, IN 46202, USA
    J Clin Oncol 24:2038-43. 2006
    ..Our trial was designed to determine if a modified weekly regimen of IP would provide superior survival with less toxicity than EP...
  5. ncbi Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer
    Nasser Hanna
    Indiana University, Indianapolis, USA
    J Clin Oncol 24:5253-8. 2006
    ..To determine the efficacy of cetuximab in patients with recurrent or progressive non-small-cell lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen...
  6. ncbi Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology
    Nasser Hanna
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA
    J Clin Oncol 26:5755-60. 2008
    ..This randomized phase III trial evaluated whether consolidation docetaxel was responsible for this improved survival...
  7. ncbi Advances in the treatment of second-line non-small-cell lung cancer
    N Hanna
    Indiana University, Indianapolis, IN 46202, USA
    Lung Cancer 50:S15-7. 2005
    ..One of these trials has subsequently led to the approval of erlotinib as second- or third-line therapy in advanced NSCLC...
  8. ncbi Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Nasser Hanna
    Indiana University, 535 Barnhill Dr, Room 473, Indianapolis, IN 46202, USA
    J Clin Oncol 22:1589-97. 2004
    ..To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy...
  9. ncbi Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed
    Nasser H Hanna
    Department of Medicine, Indiana University, Indianapolis 46202, USA
    Clin Lung Cancer 5:S75-9. 2004
    ..Based on these data, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC...
  10. ncbi Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study
    N H Hanna
    Department of Medicine, Indiana University Medical Center, Indianapolis, USA
    Ann Oncol 13:95-102. 2002
    ....
  11. ncbi A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer
    Sumeet Bhatia
    Indiana University, 535 Barnhill Drive Room 473, Indianapolis, IN 46202, USA
    Lung Cancer 38:73-7. 2002
    ..In conclusion, weekly gemcitabine with paclitaxel in patients with advanced NSCLC is an active regimen; however, toxicity and poor survival precludes the use of this regimen as an experimental arm on a future phase III study...
  12. ncbi Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study
    Sumeet Bhatia
    Department of Medicine, Indiana University, 535 Barnhill Drive Room 473, Indianapolis, IN 46202, USA
    Lung Cancer 38:85-9. 2002
    ..5 months, 45, and 17%, respectively. In conclusion, consolidation chemotherapy was associated with significant hematologic toxicity without an obvious improvement in survival in comparison to other studies utilizing chemoradiation alone...
  13. ncbi Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group
    Anuj Agarwala
    Indiana University, Indianapolis, Indiana, USA
    J Thorac Oncol 3:374-9. 2008
    ..Preclinical studies demonstrate significant interactions between the EGFR and cyclooxygenase 2 (COX-2) pathways and that simultaneous inhibition may have benefits over EGFR inhibitors alone...
  14. ncbi Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial
    A M Moore
    Indiana University School of Medicine, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202, USA
    Lung Cancer 52:93-7. 2006
    ..One year overall survival (OS) was 21% (95% CI = 6-45.6%). CONCLUSION: Although gefitinib has activity in select patients with NSCLC, this study failed to demonstrate benefit in patients with small cell lung cancer...
  15. ncbi Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group
    Shadia Jalal
    Indiana University Simon Cancer Center, Indianapolis, Indiana 46202, USA
    J Thorac Oncol 4:1420-4. 2009
    ..This study evaluates the safety and efficacy of the combination of these agents in patients with advanced NSCLC...
  16. ncbi Cetuximab in non-small cell lung cancer
    Foluso O Ademuyiwa
    Indiana University School of Medicine, Division of Hematology Oncology, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    Expert Opin Biol Ther 8:107-13. 2008
    ..Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC...
  17. ncbi Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel
    R Bryan Barriger
    Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Int J Radiat Oncol Biol Phys 78:1381-6. 2010
    ..To examine the rates and risk factors for radiation pneumonitis (RP) in non-small-cell lung cancer (NSCLC) patients treated with chemoradiotherapy...
  18. ncbi Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study
    Shadia Jalal
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indianapolis, USA
    J Thorac Oncol 4:93-6. 2009
    ..Based on the need to discover better systemic therapies, we conducted a phase II study of pemetrexed in patients with relapsed SCLC...
  19. ncbi Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group
    Shadia Jalal
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
    J Thorac Oncol 5:2008-11. 2010
    ..Angiogenesis seems to play an important role in the pathogenesis of SCLC. This study evaluated the safety and efficacy of paclitaxel plus bevacizumab in patients with chemosensitive relapsed SCLC...
  20. ncbi Combined chemoradiotherapy in small cell lung cancer
    Noah M Hahn
    Division of Hematology and Oncology, Indiana University Cancer Center, 535 Barnhill Drive, Indiana University Cancer Pavilion, Room RT473, Indianapolis, IN 46202, USA
    Hematol Oncol Clin North Am 19:321-42, vii. 2005
    ..Cisplatin and etoposide remain the preferred chemotherapy agents. New chemotherapeutic agents and novel treatment approaches are under intense investigation...
  21. ncbi Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors
    Nasser Hanna
    Indiana University, Indianapolis, Indiana, U.S.A
    Am J Clin Oncol 26:200-2. 2003
    ..In conclusion, this three-drug regimen resulted in significant cumulative myelosuppression in the doses and schedule tested in this phase I trial. Subsequent combinations of these drugs should focus on alternate doses or schedules...
  22. ncbi Large cell carcinoma of the lung mimicking a germ cell tumor: the potential value of chromosome analysis
    Syed M Ahmed
    Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Lung Cancer 49:271-4. 2005
  23. ncbi Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies
    Nasser H Hanna
    Department of Medicine, Indiana University, Indianapolis, Indiana, U.S.A
    Am J Clin Oncol 25:337-9. 2002
    ..Subsequent combinations of these drugs, if warranted, should focus on alternate doses, schedules, or routes of administration...
  24. ncbi Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma
    Leanne S Budde
    Indiana University School of Medicine, Division of Hematology Oncology, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202 USA
    Expert Rev Anticancer Ther 4:361-8. 2004
    ....
  25. ncbi Treatment of small cell lung cancer
    Anupama Kurup
    Department of Medicine, Hematology Oncology, Indiana University, Indianapolis, IN, USA
    Crit Rev Oncol Hematol 52:117-26. 2004
    ..Patients with ED frequently relapse, and relapsed/refractory SCLC has a poor prognosis. The challenge remains to identify novel therapies and molecular targets to improve survival in SCLC...
  26. ncbi Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Thomas J Lynch
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 3:S107-12. 2008
    ..A CME activity based on this summary is also available at www.informedicalcme.com/cme...
  27. ncbi Antimetabolites in the management of non-small cell lung cancer
    Leanne S Budde
    Indiana University School of Medicine, Department of Medicine, Division of Hematology Oncology, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    Curr Treat Options Oncol 6:83-93. 2005
    ....
  28. ncbi Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
    Toru Mukohara
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 97:1185-94. 2005
    ..003). CONCLUSIONS: EGFR mutations in NSCLC cells are associated with sensitivity to gefitinib but not to cetuximab...
  29. ncbi Postoperative chemotherapy for n2 non-small-cell lung cancer: conclusions are not black and white, but gray
    Nasser H Hanna
    J Clin Oncol 24:5611-2; author reply 5612-3. 2006
  30. ncbi Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy
    Anuj K Agarwala
    Department of Medicine, Division of Oncology, Indiana University, Indianapolis 46202, USA
    Clin Lung Cancer 6:367-8. 2005
    ..In the rare situation in which a patient has a solitary bone metastasis, aggressive treatment may be warranted, as illustrated by the case reported here...
  31. ncbi Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
    Thomas A Hensing
    Kellogg Cancer Center, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Anticancer Drugs 17:697-704. 2006
    ..The lack of activity in either patient subgroup, however, does not support further evaluation of this drug as a single agent in this disease...
  32. ncbi Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer
    Eric D Bernstein
    Department of Medical Oncology, Indiana University, 535 Barnhill Drive, RT 473, Indianapolis, Indiana 46202, USA
    Ann Surg Oncol 13:291-301. 2006
    ..CONCLUSIONS: Surgical resection followed by adjuvant chemotherapy is the standard of care treatment for patients with completely resected stage I, II, and IIIA non-small-cell lung cancer...
  33. ncbi A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
    Rudolph M Navari
    Notre Dame Cancer Institute, University of Notre Dame, 224 Raclin Carmichael Hall, Notre Dame, IN 46556, USA
    Support Care Cancer 15:1285-91. 2007
    ....